Related Experiment Video
Updated: May 31, 2026
06:08
Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023
Thiazolidinediones regulate adipose lineage dynamics.
Wei Tang1, Daniel Zeve, Jin Seo
1Department of Developmental Biology, University of Texas Southwestern Medical Center, 6000 Harry Hines Boulevard, Dallas, TX 75390-9133, USA.
Cell Metabolism
|July 5, 2011
Summary
Rosiglitazone, a glucose-lowering drug, significantly boosts the conversion of adipose stem cells into fat cells. However, long-term use impairs stem cell function and alters their molecular profile.
Area of Science:
- Metabolic regulation by white adipose tissue.
- Obesity and its associated complications (diabetes, atherosclerosis, cancer).
Background:
- White adipose tissue (WAT) plays a crucial role in metabolic regulation.
- The plasticity of WAT is critical for maintaining metabolic homeostasis.
- Understanding how pharmacological agents influence WAT dynamics is essential.
Purpose of the Study:
- To investigate the effects of rosiglitazone on adipose progenitor cells and stem cell compartment.
- To elucidate the impact of chronic rosiglitazone administration on adipogenesis and stem cell characteristics.
Main Methods:
- In vivo lineage marking techniques.
- Bromodeoxyuridine (BrdU) labeling strategies.
- Analysis of adipose progenitor cell differentiation and stem cell compartment properties.
Main Results:
- Rosiglitazone significantly increased the differentiation of adipose progenitors into adipocytes.
- Chronic rosiglitazone treatment disrupted the adipogenic capacity of the stem cell compartment.
- Alterations in the molecular characteristics of the adipose stem cell compartment were observed.
Conclusions:
- Pharmacological stimuli, like rosiglitazone, can profoundly influence adipose tissue dynamics.
- Chronic rosiglitazone administration negatively impacts adipose stem cell function.
- These findings offer insights into manipulating adipose lineage for therapeutic interventions in metabolic diseases.
Related Concept Videos
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood glucose levels...
01:24Type II Diabetes II: Pathophysiology
PathophysiologyType 2 diabetes mellitus (T2DM ) is a chronic metabolic disorder characterized by insulin resistance and progressive pancreatic β-cell dysfunction, leading to impaired glucose homeostasis. It results from interactions among genetic predisposition, environmental factors, and metabolic stressors, such as overnutrition and a sedentary lifestyle.Insulin Resistance and Glucose DysregulationEarly T2DM involves insulin resistance in skeletal muscle, adipose tissue, and the liver.
01:24Glucagon-like Receptor Agonists
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
01:28Insulin: The Receptor and Signaling Pathways
Insulin action is mediated through a receptor tyrosine kinase, akin to the IGF-1 receptor. The number of receptors per cell varies significantly, from 40 on erythrocytes to 300,000 on adipocytes and hepatocytes. The insulin receptor consists of linked α/β subunit dimers, forming a heterotetramer glycoprotein with two extracellular α subunits and two β subunits spanning the membrane. The α subunits inhibit the inherent tyrosine kinase activity of the β subunits, but this inhibition is released...
01:26Type II Diabetes I: Introduction
Type 2 diabetes mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance, in which target tissues such as the liver, muscle, and adipose tissue respond poorly to insulin. It is also associated with inadequate compensatory insulin secretion, where pancreatic β-cells fail to produce sufficient insulin. Together, these abnormalities lead to persistent hyperglycemia.EtiologyT2DM develops through a complex interaction of genetic predisposition and environmental or...
01:23Dipeptidyl Peptidase 4 Inhibitors
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a significant...